Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
People with endometrial cancer often gain weight during and after chemotherapy. Medicines to reduce the risk of an allergic reaction for people receiving chemotherapy can also raise blood sugar. Weight gain can affect overall health and cancer recovery.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are assessing ado-trastuzumab emtansine (T-DM1) to treat salivary gland cancer. The people in this study have cancer that is operable (can be removed with surgery) and makes a protein called HER2. T-DM1 targets cancer cells that make HER2. In this study, it will be combined with radiation therapy and chemotherapy after the tumor has been removed by surgery.
Researchers want to see if the herbal supplement Ma-Zi-Ren-Wan (MZRW) helps relieve chronic constipation in survivors of cancer. They will also see how MZRW affects the gut microbiome.
Researchers want to find the best doses of RMC-6291 and RMC-6236 when given together to treat lung cancer and other types of cancer that have KRAS G12C mutations. The people in this study have advanced non-small cell lung cancer (NSCLC) or colorectal cancer with a gene mutation (change) called KRAS G12C.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
A mutation called G12C in a gene called KRAS may promote cancer growth. LY3537982 is an investigational drug that targets the mutated KRAS G12C protein. This targeting action may stop cancer cells from growing and dividing.
Anaplastic large cell lymphoma (ALCL) is a type of T-cell cancer. This cancer has a fusion (change) in the ALK gene. The fusion gene makes a protein that promotes cancer growth and survival. This type of cancer is called ALK-positive ALCL.
Researchers in this study are assessing the combination of enfortumab vedotin with pembrolizumab immunotherapy in people with bladder cancer that has spread to nearby lymph nodes and will be surgically removed. Both medications are already used to treat bladder cancer, but their use together before surgery is considered investigational. Both drugs help the immune system attack and kill cancer cells. The study investigators will see if this combination treatment can get rid of cancer in the lymph nodes and shrink patients' tumors before surgery.
Researchers are comparing three different treatments for multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment. If you join this study, you will be randomly assigned to get one of these treatments:
